NeuroRx and Relief Therapeutics have secured fast track designation from the US Food and Drug Administration (FDA) to evaluate RLF-100 (Aviptadil) to treat acute lung injury/acute respiratory distress syndrome associated with Covid-19.
Deciphera Pharmaceuticals announced that Health Canada has authorized QINLOCK (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
Indian drugmaker Cipla has introduced the generic version of remdesivir, dubbed Cipremi, to treat patients with severe Covid-19 disease.
The Indian Central Drugs Standard Control Organisation (CDSCO) has approved the use of Glenmark Pharmaceuticals' generic for Favipiravir and Cipla and Hetero Drugs' respective generics for Remdesivir for the treatment of Covid-19 patients.
After transferring the media slurry into the open column, the piston is quickly mounted in a way that avoids air entry, and the column is sealed.
Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for TAZVERIK™ (tazemetostat) for the following two distinct follicular lymphoma (FL) indications.
Novartis has secured approval from the US Food and Drug Administration (FDA) for its Cosentyx (secukinumab) to treat active non-radiographic axial spondyloarthritis (nr-axSpA).
Jazz Pharmaceuticals and PharmaMar have secured accelerated approval from the US Food and Drug Administration (FDA) for Zepzelca (lurbinectedin) for the treatment of metastatic small cell lung cancer (SCLC).
NeoImmuneTech, a clinical-stage T cell-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NeoImmuneTech’s NT-I7 (efineptakin alfa), the only clinical-stage long-acting human IL-7, for the treatment of Progressive Multifocal Leukoencephalopathy (PML).
ViiV Healthcare has been granted approval by the US Food and Drug Administration (FDA) for Tivicay (dolutegravir) tablets and Tivicay PD (dolutegravir) tablets for suspension for the treatment of human immunodeficiency virus type 1 (HIV-1) in infants and children.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.